Targets › UGT1A1
2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Metabolic and endocrine; next expected readout Nov 2027.
[Isoform 1]: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile. Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds. (UniProt, P22309)
Open in Phaseline: the race on UGT1A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Genethon | GNT0003 AAV8 vector carrying UGT1A1 transgene for gene therapy | UGT1A1 | Phase 2 | Crigler-Najjar Syndrome | Sep 2030 |
| Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare | GT-UGT1A1-AAV8-02 AAV8-mediated gene therapy delivering UGT1A1 gene | UGT1A1 | Phase 1 | Crigler-Najjar Syndrome Type I | Nov 2027 |
Crigler-Najjar Syndrome Type I (1) Crigler-Najjar Syndrome (1)
other (1), mixed (1)
Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare (1) Genethon (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.